© Copyright Acquisition International 2025 - All Rights Reserved.

Article Image - Evotec Announces Its Intent to Acquire Cyprotex Plc
Posted 26th October 2016

Evotec Announces Its Intent to Acquire Cyprotex Plc

Acquisition would add world-leading high-quality ADME-Tox services and strengthen Evotec's leadership in drug discovery

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Evotec Announces Its Intent to Acquire Cyprotex Plc
Image

Evotec Announces Its Intent to Acquire Cyprotex Plc

Acquisition would add world-leading high-quality ADME-Tox services and strengthen Evotec’s leadership in drug discovery

– Evotec will pay approximately £ 55.36 m (EUR 62.00 m) in cash for the full share capital of Cyprotex and funding of all existing debt of the AIM-listed company

– Proposed acquisition, unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that it has made an offer to acquire Cyprotex PLC (“Cyprotex”, AIM: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK. Cyprotex serves the industry’s increasing requirement for earlier drug screening, regulatory requirements and reducing the reliance on animal testing.

The proposed acquisition, which has been unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016. Evotec will pay approximately £ 55.36 m (EUR 62.00 m; £/EUR exchange rate of 1.12) in cash for the acquisition of all 26.1 million issued and to be issued Cyprotex shares and the funding of all existing company debt. The offer of 1.60 £ per Cyprotex share reflects a 9.4% premium to the VWAP of the past 30 trading days at AIM. The offer is intended to be implemented by a scheme of arrangement regulated by the UK takeover code, with already >50% shares secured irrevocable. The acquisition will add to Evotec’s revenues and be accretive to Evotec’s 2017 EBITDA.

Cyprotex is the world’s largest contract research organisation specialising in pre-clinical ADME-Tox and DMPK serving the Pharmaceutical, Chemical, Agrochemical and Cosmetics markets. Cyprotex, headquartered in the UK, was founded in 1999 and is publicly traded on AIM (CRX). It has 136 employees working from sites at Macclesfield and Alderley Park, both of which are located near Manchester in the UK, and at Watertown, MA, and Kalamazoo, MI, in the USA. With more than 1,500 partners, Cyprotex has a very strong customer network. Cyprotex reported H1 2016 revenues of £ 8.73 m (EUR 9.78 m) (H1 2015: £ 6.93 m (EUR 7.76 m)) with an underlying EBITDA of £ 2.34 m (EUR 2.62 m) (H1 2015: £ 1.10 m (EUR 1.23 m)).

Sharpening Evotec’s leadership role in drug discovery The acquisition strengthens Evotec’s high-end drug discovery platform and capabilities with access to the market’s most industrialised ADME-Tox platform and proven expertise in in vitro ADME screening, mechanistic and high-content toxicology screening and predictive modelling.

This perfectly augments Evotec’s drive for innovation efficiency in drug discovery by enabling its partners to make early informed decisions on a molecule’s suitability for further development. The Cyprotex platform can be leveraged in a high-throughput manner or to support integrated drug discovery projects.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “The ability to test or predict a molecule’s suitability as a drug at an early stage is critical in the drive to increase the efficiency of drug discovery.

The proposed acquisition of Cyprotex is a completely logical step to strengthen Evotec’s position as the world’s leading partner of choice for driving such efficiencies in drug discovery to the industry. The proven technology platform of Cyprotex and its expert and dedicated employees will be a strong addition to our best-in-class drug discovery platform and resources. We also expect that both organisations will leverage their extensive partner networks to identify further commercial synergies.”

Dr Werner Lanthaler, Chief Executive Officer of Evotec, added: “Our focus to make the most innovative and capital efficient drug discovery platform will be perfectly extended by Cyprotex. Given our strong performance over the last years, a very good outlook of our business into the coming years, and the commercial profile of Cyprotex we also feel very comfortable in using the cash on our strong balance sheet for this accretive acquisition. We are very much looking forward to welcoming the employees of Cyprotex within the Evotec Group after closing of the transaction.”

Categories: Innovation, Leadership


You Might Also Like
Read Full PostRead - Eye Icon
Employment Screening Solution Innovation
Leadership
21/12/2021Employment Screening Solution Innovation

Cisive is a global provider of compliance-driven human capital management and risk management solutions. Its expert team understands the risks and regulations that apply to the financial services, healthcare, transportation, and other highly regulated industri

Read Full PostRead - Eye Icon
451 Research Identifies Nearly 300 M&A and IPO Candidates in its Annual 2016 Tech M&A Outlook
Innovation
25/02/2016451 Research Identifies Nearly 300 M&A and IPO Candidates in its Annual 2016 Tech M&A Outlook

According to 451 Research’s recently published Tech M&A Outlook 2016, acquirers will spend hundreds of billions of dollars on tech acquisitions in the coming year to adapt to a rapidly changing marketplace with notable hotspots in information security, IoT a

Read Full PostRead - Eye Icon
Why Data is and Always Will Be The Next Big Thing
Innovation
07/08/2020Why Data is and Always Will Be The Next Big Thing

Data has ushered in a new digital era for businesses, society and individuals – one that’s revolutionizing customer and employee experiences, creating more dynamic, responsive, and personalised business models, and even sparking entirely new industries.

Read Full PostRead - Eye Icon
Over 35 Years of Sensational Success
Legal
17/01/2023Over 35 Years of Sensational Success

Complex litigation law can be extremely challenging to navigate however, with a strong, level-headed load of experience, we find ourselves in good hands with Marc J. Bern & Partners LLP.

Read Full PostRead - Eye Icon
How to Lower Your Car Insurance Payments Fast
Finance
12/01/2023How to Lower Your Car Insurance Payments Fast

Everyone would like to lower the cost of their car insurance payments. However, not everybody actually looks at active ways to reduce the cost of their auto insurance. If that’s you, it’s time to change your ways. So, check out the following helpful advice

Read Full PostRead - Eye Icon
Disability-related tribunal cases increase 133% over past five years – making it one of the most prevalent types of workplace discrimination
Legal
26/02/2021Disability-related tribunal cases increase 133% over past five years – making it one of the most prevalent types of workplace discrimination

Disability-related tribunal cases have increased 133% over the past five years, making it the second most prevalent type of workplace discrimination, new research shows.

Read Full PostRead - Eye Icon
Orrick Advises Shareholders in Sale of Slovakian Telecoms Provider Benestra
Finance
26/05/2016Orrick Advises Shareholders in Sale of Slovakian Telecoms Provider Benestra

Orrick has advised a consortium of international private equity firms, including Bessemer Venture Partners, Columbia Capital, HarbourVest Partners, Innova Capital, MC Partners and Oak Investment Partners, in the sale of Slovakian telecommunications provider Be

Read Full PostRead - Eye Icon
Preventing Legal Hassles: Why Workers’ Compensation Insurance is Crucial for Businesses
Legal
07/08/2023Preventing Legal Hassles: Why Workers’ Compensation Insurance is Crucial for Businesses

When it comes to running a business, there are many factors to consider, including the well-being and safety of your employees.

Read Full PostRead - Eye Icon
A New Dawn for Britishvolt and the UK’s Electric Vehicle Battery Industry
Innovation
02/03/2023A New Dawn for Britishvolt and the UK’s Electric Vehicle Battery Industry

With efforts being made globally to phase out the use of petrol and diesel-powered vehicles in the coming years, several companies have stepped up to research and develop innovative technologies for electric vehicle expansion.



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow